首页> 外文期刊>Journal of the Canadian Association of Gastroenterology >DIFFERENCES BETWEEN HUMAN AND MOUSE INTESTINAL EPITHELIAL CELLS IN THEIR INNATE IMMUNE RESPONSES TO BACTERIAL AND HOST STIMULI.
【24h】

DIFFERENCES BETWEEN HUMAN AND MOUSE INTESTINAL EPITHELIAL CELLS IN THEIR INNATE IMMUNE RESPONSES TO BACTERIAL AND HOST STIMULI.

机译:人和小鼠肠上皮细胞与细菌和宿主刺激的先天免疫反应之间的差异。

获取原文
           

摘要

Background Intestinal epithelial cells (IEC) reside in close contact with the gut microbiota. It is thus important that IEC are hypo-responsive to bacterial products to prevent maladaptive inflammatory responses in the gut, such as those seen in Inflammatory bowel diseases (IBD). This suppression of innate immune signaling in IEC is in part due to their strong expression of Single Ig IL1 related receptor (SIGIRR), a negative regulator of interleukin (IL)-1 and toll-like receptor (TLR) signaling. IL37, a newly recognized anti-inflammatory cytokine has been shown to strongly inhibit innate signaling in cells by binding to, and signaling through SIGIRR, leading to suppression of various forms of inflammation in mice. Few studies have looked at the function of IL-37/SIGIRR in IEC and their potential use to balance inflammatory responses. Notably, while many groups have studied IEC immune response in vitro , using transformed IEC lines, our focus is on primary-derived IEC which more accurately reflect in vivo responses. Aims To characterize IEC intrinsic and species-specific immune responses elicited by bacteria and host products as well as the role of IL37/SIGIRR in regulating this innate signaling. Methods We used organoid to study the innate immune responses of primary IEC derived from human or mouse colon (colonoids). After stimulation with inflammatory stimuli (IL1β, FliC and LPS), qPCR, ELISA, Milliplex Multiplex Assay and Western blot were used to determine modification in signalling pathway and cytokine/chemokine secretion. Results Using colonoids derived from healthy donors, we demonstrated that unlike transformed cell lines or mouse IEC, human IEC respond only to the bacterial product FliC, and not to LPS or IL1β. We further characterized human colonoid innate immune responses and despite significant inter-individual variability upon FliC stimulation, all organoids released several chemokines (IL8, CXCL1, CXCL2, CCL2 and CCL20). We showed for the first time that IL37 attenuated these innate immune responses through inhibition of intracellular signaling pathways (p38 and NFkB). Using colonoids derived from wildtype and Sigirr deficient mice, we found that mice IEC were responsive to IL1b and FliC and that the suppressive effects of IL37 were Sigirr dependent. Conclusions Our results show that human IEC show variability among individuals in the magnitude of their innate immune responses, and these responses differ from those obtained from transformed cells and primary mouse IEC. For the first time, we show that IL37 suppresses IEC innate immune responses, through its ability to signal through Sigirr. Further investigations will assess the ability of IL37 to control inflammation of IEC derived from IBD patients, as a potential therapeutic to promote gut health.
机译:背景技术肠上皮细胞(IEC)与肠道微生物肿块紧密接触。因此重要的是,IEC对细菌产物的敏感性敏感,以防止肠道中的不良炎症反应,例如在炎症性肠病(IBD)中看到的那些。这种抑制IEC中的先天免疫信号传导部分是由于它们的单Ig IL1相关受体(SigIrr)的强表达,白细胞介素(IL)-1的负调节剂和Toll样受体(TLR)信号传导。 IL37,已经证明了一种新公认的抗炎细胞因子通过结合和通过SigOrr来强烈抑制细胞中的先天信号传导,导致小鼠中各种形式的炎症抑制。很少有研究看过IEC中IL-37 / Sigor的功能及其潜在用来平衡炎症反应。值得注意的是,虽然许多群体在体外研究了IEC免疫反应,但使用转化的IEC线路,我们的重点是在初级衍生的IEC上,更准确地反映体内反应。旨在表征细菌和宿主产品引发的IEC内在和物种特异性免疫应答以及IL37 / Sigror在调节该先天信号时的作用。方法采用有机体研究源自人或小鼠结肠(上衣)原发性IEC的先天免疫应答。用炎性刺激(IL1β,FLIC和LPS)刺激后,使用QPCR,ELISA,毫耳多重测定和Western印迹来确定信号通路和细胞因子/趋化因子分泌中的修饰。结果使用来自健康供体的上衣,我们证明与转化的细胞系或小鼠IEC不同,人体IEC仅响应细菌产物Flic,而不是LPS或IL1β。我们进一步表征了人性上衣先天免疫应答,尽管在流体刺激时,尽管存在显着的间下变异性,但所有有机体释放出几种趋化因子(IL8,CXCL1,CXCL2,CCL2和CCL20)。我们首次显示IL37通过抑制细胞内信号通路(P38和NFKB)来衰减这些先天免疫应答。使用源自野生型和Sigirr缺乏小鼠的上衣,我们发现小鼠IEC对IL1B和FLIC响应,并且IL37的抑制作用是棘爪的。结论我们的研究结果表明,人类IEC在其先天免疫应答的幅度下表现出变异性,这些反应与转化细胞和原发性小鼠IEC获得的反应不同。我们首次表明IL37通过其通过SigIrr发出的能力来抑制IEC先天免疫应答。进一步的调查将评估IL37控制IEC衍生自IBD患者的IEC炎症的能力,作为促进肠系健康的潜在治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号